June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Transcriptomic and exomic sequencing analysis of the living library for uveal melanoma
Author Affiliations & Notes
  • Cynthia Pfannkoch
    Ophthalmology, Mayo Foundation for Medical Education and Research, Rochester, Minnesota, United States
  • Sam Adams Erickson
    Ophthalmology, Mayo Foundation for Medical Education and Research, Rochester, Minnesota, United States
  • David R Miley
    Ophthalmology, Mayo Foundation for Medical Education and Research, Rochester, Minnesota, United States
  • Lauren A Dalvin
    Ophthalmology, Mayo Foundation for Medical Education and Research, Rochester, Minnesota, United States
  • Footnotes
    Commercial Relationships   Cynthia Pfannkoch None; Sam Erickson None; David Miley None; Lauren Dalvin None
  • Footnotes
    Support  Leonard and Mary Lou Hoeft Career Development Award Fund in Ophthalmology Research, Grant Number P30 CA015083 from the National Cancer Institute, and CTSA Grant Number KL2 TR002379 from the National Center for Advancing Translational Science (NCATS).
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 913. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Cynthia Pfannkoch, Sam Adams Erickson, David R Miley, Lauren A Dalvin; Transcriptomic and exomic sequencing analysis of the living library for uveal melanoma. Invest. Ophthalmol. Vis. Sci. 2023;64(8):913.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To explore the transcriptomic and exomic landscape of patient-derived uveal melanoma organoids (PDOs).

Methods : Patients with primary choroidal or ciliochoroidal melanoma undergoing enucleation from 7/1/2019-9/30/2022 were invited to enroll. Tumor tissue was harvested within 30 minutes of globe removal. Cells were isolated using the gentleMACS human tumor dissociation kit (Miltenyi Biotech), plated on Cultrex-coated multiwell plates, and cultured in supplemented RPMI media. Five PDOs were selected for transcriptomic sequencing (RNA-Seq) at passage 1 (P1) and P3, with 4 PDOs selected for whole exome sequencing (WES) at P1. RNA isolation was performed using a modified Zymo RNA clean and concentrator kit and DNA isolation using a Zymo Quick DNA microprep kit. Library construction, sequencing, and transcriptome/exome analysis were contracted to Genewiz (Azenta Biosciences).

Results : PDOs were established in 19 of 20 (95%) attempted cases. All 19 patients were white, with 12 male and mean age 60 years (median 58, range 37-101). Pathology stage was pT2a (n=1), pT3a (n=4), pT3b (n=3), or pT4b (n=11), with cell type spindle (n=4), mixed (n=11), or epithelioid (n=4). BAP1 protein expression was retained (n=7) or lost (n=12), with matching phenotype confirmed in PDOs. DecisionDx-UM testing in 12 cases revealed Class 1B PRAME-negative (n=2), Class 1B PRAME-positive (n=3), Class 2 PRAME-negative (n=1), or Class 2 PRAME-positive (n=6). In 9 sequenced primary tumors, a driving mutation was present in GNAQ (n=4), GNA11 (n=4), or CYSLTR2 (n=1). PDOs displayed varying morphology, ranging from broad-based spindle-like structures with abundant communications to discrete clusters of epithelioid-like cells. Over time, most PDOs demonstrated increasing pigmentation and ultimately formed discrete organoid clusters. Growth in culture was slow, and 1-2 months were allotted prior to passaging in most cases. RNA-Seq and WES confirmed distinct molecular profiles. RNA-Seq in 5 PDOs indicated no significant changes in gene expression between P1 and 3. However, between-PDO analysis of both RNA-Seq and WES revealed stability of unique molecular phenotypes consistent with those of the primary tumor.

Conclusions : We have established a bank of uveal melanoma PDOs for use in drug studies and demonstrated stability of unique RNA-Seq and WES profiles through passaging.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×